Vanda Pharmaceuticals Posts Strong Growth in Q2 2025 Financial Results Amid New Drug Approvals Vanda Pharmaceuticals Inc. announces significant financial growth for Q2 2025, highlighted by increased product sales. The company also anticipates critical FDA reviews.

Vanda Pharmaceuticals Posts Strong Growth in Q2 2025 Financial Results Amid New Drug Approvals #USA #Washington #Vanda_Pharmaceuticals #Fanapt #Bysanti

Vanda Pharmaceuticals to Present Key Findings at ASCP Annual Meeting 2025 Vanda Pharmaceuticals is set to participate in the ASCP Annual Meeting 2025, showcasing their innovative findings on new psychiatric therapeutics.

Vanda Pharmaceuticals to Present Key Findings at ASCP Annual Meeting 2025 #United_States #Scottsdale #Vanda_Pharmaceuticals #Bysanti #ASCP_Annual_Meeting

Vanda Pharmaceuticals Reports Strong Q1 2025 Results Highlighting Robust Growth and New Drug Developments Vanda Pharmaceuticals showcases impressive Q1 2025 financial results, highlighting growth in Fanapt® prescriptions and advancements in new drug applications.

Vanda Pharmaceuticals Reports Strong Q1 2025 Results Highlighting Robust Growth and New Drug Developments #USA #Washington #Vanda_Pharmaceuticals #Fanapt #Bysanti